{"slug":"hexarelin","seoKey":"hexarelin","inn":"examorelin","displayName":"Hexarelin","codes":["EP-23905","MF-6003"],"synonyms":["examorelin","EP23905","examorelina","examoreline","examorelinum","hexarelin acetate","His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2"],"legalClass":"research_chemical","identifiers":{"cas":"140703-51-1","pubchemCid":6918297,"unii":"09QF37C617","inchikey":"RVWNMGKSNGWLOL-GIIHNPQRSA-N","drugbankId":"DB19510","chemblId":"CHEMBL108335","wikidataQid":"Q21098927","formula":"C47H58N12O6","molecularWeight":887,"sequence":"His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: three separate negative findings on 2026-09-10. A query of the agency's drug label database for the substance under both of its names returned no records, while a control query for semaglutide returned five labels in the same run. The substance appears nowhere on either compounding page: it is in none of the three categories of substances nominated for compounding under section 503A, and it is not on the list of bulk substances that may present significant safety risks. That page was checked with ipamorelin as a positive control, which appears on it ten times. The absence therefore means no agency decision has been taken on this substance, not that it has been found safe. It is nonetheless in circulation: a warning letter dated 2025-12-08 to a bulk supplier objected to that firm's drug listing for a hexarelin acetate product.","date":"2026-09-10","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"Not approved: no centrally authorised medicinal product. The finding is honest about its limits — the regulator's full-text search returned HTTP 401 from this environment on 2026-09-10 and could not be queried directly. It rests instead on the absence of any registration in every other register checked, on the absence of any trade name across the literature since 1994, and on a 2026 review that expressly counts the substance among those without regulatory approval.","date":"2026-09-10","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=hexarelin"},{"market":"DE","status":"not_approved","note":"Not approved on two levels. Under medicines law there is neither a centralised nor a national marketing authorisation, so no finished medicinal product containing the substance may be placed on the market, and the advertising restrictions for unauthorised medicines apply to any public-facing claim. Under anti-doping law the substance is named in the annex to section 2(3) of the anti-doping act, in part II.2.4 on peptides acting like growth hormone releasing factors, alongside GHRP-2 (pralmorelin), GHRP-2-Gly, GHRP-6 and GHRP-6-Gly. It is listed there under its own name, which is a qualitative difference from substances caught only by a catch-all clause.","date":"2026-09-10","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: no marketing authorisation known, and unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012. The finding is of limited depth — the regulator's product database returned only a JavaScript shell without a server-rendered result list on 2026-09-10, and the search interface behind it could not be reached, so this is not backed by a register query of its own.","date":"2026-09-10","source":"https://products.mhra.gov.uk/search/?search=hexarelin"},{"market":"AU","status":"scheduled","date":"2026-05-28","note":"The strictest documented classification of any market, quoted verbatim rather than inferred: the Poisons Standard carries the Schedule 4 entry marked with a hash, which the footnote on the same page defines as also listed in Appendix D, and the index of the instrument confirms both Schedule 4 and Appendix D, clause 5. In the Appendix D table the substance is item 22, next to the collective entries for growth hormone releasing peptides and growth hormone secretagogues. Clause 5 is headed poisons for which possession without authority is illegal, and section 64(4) states that such a poison must not be possessed without authority under the law of the jurisdiction where the possession occurs. So the substance is not merely prescription-only: bare possession without authorisation is unlawful. No registered finished product is known, though the product register itself timed out on 2026-09-10 and that part is an assessment rather than a register finding.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned zero records for both of the substance's names on 2026-09-10.","date":"2026-09-10","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=hexarelin"},{"market":"CH","status":"not_approved","note":"Not approved: no marketing authorisation known. The finding is of limited depth — no register could be queried directly in this session on 2026-09-10, so it is an inference from the worldwide absence of any authorisation rather than a register finding of its own. Independently of that, distributing or brokering unauthorised medicinal products is unlawful in this market.","date":"2026-09-10","source":"https://www.swissmedicinfo.ch/"}],"devStage":"discontinued","strongestEvidence":"rct_phase1","wada":{"status":"prohibited","section":"S2.2.4","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q21098927","https://pubchem.ncbi.nlm.nih.gov/compound/6918297"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"Hexarelin: what the studies show, status and safety","summary":"Hexarelin is a lab-made peptide of six building blocks that prompts the pituitary gland to release growth hormone, by docking onto the receptor for the hunger hormone ghrelin. Researchers in Milan and Argenteuil described it in 1994, and more than a hundred papers went on to test it in people. Almost all of them gave one dose and measured a hormone level, and the single study that treated adults for four months found no change in the growth factor IGF-I, in body fat, in lean mass or in bone. No country has ever approved it, and the world anti-doping list names it.","updated":"2026-09-10","url":"https://mypep.app/peptides/hexarelin"}